Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavo + Pembrolizumab in Advanced Melanoma
NCT03132675Phase 2Unknown
- Sponsor
- OncoSec Medical
- Start
- Oct 2017
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 5
01
Overview
Phase 2, open-label trial of tavokinogene telseplasmid in melanoma, sponsored by OncoSec Medical. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
tavokinogene telseplasmid
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03132675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132675.